CMS 130 Colorectal Cancer Screening

XMLWordPrintable

    • Type: EC eCQMs - Eligible Clinicians
    • Resolution: Answered
    • Priority: Moderate
    • Component/s: None
    • None
    • Renee Martinez
    • 3076337442
    • Hide
      Thank you for your inquiry regarding CMS130v14 (2026 Performance Period). This measure is based on the guidelines from the U.S. Preventive Services Task Force (USPSTF), which does not recognize the CRC blood test as an acceptable option for meeting the measure's criteria. To meet the numerator requirements, applicable screenings include Fecal Occult Blood Test, Stool DNA with Fecal Immunochemical Test (FIT), Flexible Sigmoidoscopy, CT Colonography, or a colonoscopy. Clinically equivalent services may be mapped to the codes used in a measure's value sets to satisfy a value set requirement. If mapping is conducted, you should maintain documentation in case of a CMS audit. Please review the measure specification for further details about measure requirements: https://ecqi.healthit.gov/sites/default/files/ecqm/measures/CMS130-v14.0.000-QDM.html.
      Show
      Thank you for your inquiry regarding CMS130v14 (2026 Performance Period). This measure is based on the guidelines from the U.S. Preventive Services Task Force (USPSTF), which does not recognize the CRC blood test as an acceptable option for meeting the measure's criteria. To meet the numerator requirements, applicable screenings include Fecal Occult Blood Test, Stool DNA with Fecal Immunochemical Test (FIT), Flexible Sigmoidoscopy, CT Colonography, or a colonoscopy. Clinically equivalent services may be mapped to the codes used in a measure's value sets to satisfy a value set requirement. If mapping is conducted, you should maintain documentation in case of a CMS audit. Please review the measure specification for further details about measure requirements: https://ecqi.healthit.gov/sites/default/files/ecqm/measures/CMS130-v14.0.000-QDM.html .
    • CMS1264v1
    • CMS0130v14
    • additional colorectal cancer screening option would improve performance.

      We have been contacted by Guardant Health in regards to offering the Shield Blood Test for Colorectal Cancer Screening. My understanding at this time is that it is FDA approved. Will the Shield Test be an acceptable screening tool for eCQM CMS 130 Colorectal Cancer Screening for performance year 2026?

            Assignee:
            AIR EC eCQM Team
            Reporter:
            Renee Martinez
            Votes:
            0 Vote for this issue
            Watchers:
            3 Start watching this issue

              Created:
              Updated:
              Resolved:
              Solution Posted On: